Carbenoxolone

Overview

Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction ( Gap junction ) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis.

Application

Products | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Hepatic Fibrosis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Liver Disease | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Amyloid-β | Products > Signaling Pathways > Gap Junction Protein

Product Information

• Catalog No.: HY-B1588
• CAS No.: 5697-56-3
• Molecular Formula: C34H50O7
• Molecular Weight: 570.76
• Purity: 99.9%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.38 mM); Clear solution
• Availability: In-stock

Source

Original product source